India pharmaceutical government procurement in 2024 was driven by strategic policies, increased investments, and initiatives focused on domestic manufacturing, reducing import dependence, and ensuring affordable medicines. Programs such as the Production Linked Incentive (PLI) schemes, Government e-Marketplace (GeM), and Pradhan Mantri Bharatiya Janaushadhi Pariyojana (PMBJP) played a crucial role in shaping the sector’s procurement landscape.
Total Government Spending on Pharmaceuticals
India’s government spending on pharmaceuticals in 2024 reflects its commitment to strengthening domestic production and improving public healthcare access.
Key Budget Allocations:
- Total Budget for Department of Pharmaceuticals: ₹4,089.95 crore.
- PLI Scheme for Pharmaceuticals: ₹28,328 crore to promote domestic drug manufacturing.
- PLI Scheme for Bulk Drugs: ₹3,715 crore to boost local production of essential raw materials.
- Government e-Marketplace (GeM) Procurement: A substantial portion of pharma-related purchases were made through this online public procurement platform.
- PMBJP Funding: Strengthening the availability of affordable generic medicines through 9,000+ government-supported pharmacies.
Top Buyers in Government Pharmaceutical Procurement
The largest buyers of pharmaceuticals in India include government agencies and public sector entities responsible for healthcare services.
- Ministry of Health and Family Welfare (MoHFW): Oversees nationwide drug procurement and public health programs.
- Central Government Health Scheme (CGHS): Supplies medicines to government employees, pensioners, and their families.
- State Health Departments: Handle healthcare procurement for public hospitals and clinics at the state level.
- Government Medical Colleges & Hospitals: Procure essential medicines and vaccines for public healthcare facilities.
- Defense & Railways Health Services: Supply medicines for military personnel and railway employees.
- Public Sector Undertakings (PSUs) in Pharmaceuticals: Government-run pharma companies engaged in bulk drug procurement.
Top Products Procured by the Government
India’s pharmaceutical procurement in 2024 focused on chronic disease management, essential medicines, and vaccines.
- Diabetes & Obesity Treatments: Rising demand for innovative therapies.
- Anti-Infective & Antibiotics: Essential for public hospitals and medical centers.
- Cardiovascular Drugs: Crucial for heart disease treatment.
- Oncology Drugs: Increased procurement for cancer treatment programs.
- Vaccines & Immunization Products: Large-scale purchases of COVID-19, flu, and routine vaccines.
- Bulk Drugs & Active Pharmaceutical Ingredients (APIs): Supporting domestic production of critical raw materials.
India Strengthens Global Pharma Exports
India continues to solidify its position as the “Pharmacy of the World” by expanding generic medicine exports to Africa, Latin America, and Southeast Asia. With strong government backing, Indian pharmaceutical firms play a crucial role in global healthcare by supplying affordable, high-quality medicines worldwide.
Conclusion
India’s 2024 pharmaceutical procurement strategy highlights a strong push for domestic manufacturing, strategic government initiatives, and increasing global influence. With massive investments in local production, transparent procurement platforms, and affordability-driven policies, the nation is set to enhance drug accessibility and healthcare efficiency for years to come.
#IndiaPharma #PharmaProcurement #GovernmentTenders #GlobalTenders #PharmaManufacturing #PLIPharma #GeMProcurement #AffordableMedicines #HealthcareIndia #PharmaInvestment #GenericMedicines #PublicHealth #VaccineProcurement #MedicalTenders #CDSCO #NPPA #DrugProcurement #PharmaExports #MakeInIndia #PharmaGrowth #IndianPharmaceuticals